Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...

Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...

The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...

EU approves Alexion’s Koselugo for plexiform neurofibromas in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, October 29, 2025, 11:00 Hrs [IST] Alexion, AstraZene ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...

Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by ...